Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

V. R. Aroda, A. Ahmann, B. Cariou, F. Chow, M. J. Davies, E. Jódar, R. Mehta, V. Woo, I. Lingvay

Research output: Contribution to journalReview article

19 Scopus citations

Fingerprint Dive into the research topics of 'Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials'. Together they form a unique fingerprint.

Medicine & Life Sciences